AbbVie Reports Mixed Quarter Amid Pipeline Progress and Competitive Pressures

AbbVie reported quarterly earnings results on Wednesday, February 4th, posting $2.71 earnings per share for the quarter and beating consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion, representing a 10.0% increase compared to the same quarter last year when the firm posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS.

The company announced a $380 million build-out of two active pharmaceutical ingredient (API) facilities at its North Chicago campus to support next-generation neuroscience and obesity medicines, expanding domestic capacity to support long-term product supply and commercialization. The U.S. FDA approved the combination of Venclexta and acalabrutinib for previously untreated chronic lymphocytic leukemia (CLL), which could expand label use and drive additional oncology revenue.

AbbVie reported encouraging Phase 1 data for ABBV-295, a pipeline asset that, if validated, could add to diversification beyond its current franchise. The company advanced a risankizumab dosing study, signaling continued investment in immunology development that supports medium-term growth assumptions. AbbVie also advanced ABBV-8736 into a Phase 1 trial comparing injection routes and progressed a toxin-based therapy in a Phase 2 ventral hernia trial. Completion of a Korean post-market study added supportive real-world evidence for Rinvoq adoption in immunology.

UCB's Bimzelx beat AbbVie's Skyrizi in psoriatic arthritis, a direct competitive loss that raises near-term sales and market-share concerns for a key growth driver. AbbVie filed suit challenging HHS/CMS's selection of Botox for Medicare drug-price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty.

Several equities analysts weighed in on the stock. RBC Capital initiated coverage with an Outperform rating and a $260 price target, highlighting that AbbVie's Skyrizi and Rinvoq growth and early immunology momentum still leave upside for investors. HSBC raised AbbVie from a "hold" rating to a "buy" rating and increased their target price for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Piper Sandler lifted their price objective on shares of AbbVie from $289.00 to $299.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 18th. Scotiabank assumed coverage on shares of AbbVie in a research report on Thursday, November 13th, issuing a "sector outperform" rating and a $280.00 price target on the stock. Evercore lowered their price target on AbbVie from $232.00 to $228.00 and set an "outperform" rating for the company in a research note on Wednesday, February 4th.

Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. The company currently has a consensus rating of "Moderate Buy" and a consensus target price of $253.15.

The business declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%.

The stock traded down 2.5% during mid-day trading on Friday, trading as low as $219.44 and last trading at $219.7260. The company has a market capitalization of $388.51 billion, a P/E ratio of 93.10, a P/E/G ratio of 0.79 and a beta of 0.34. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.